Ascend annuncia aumenti di prezzo per i materiali intermedi
HOUSTON, 4 novembre 2020 /PRNewswire/ -- Ascend Performance Materials ha annunciato oggi un aumento dei prezzi dei materiali intermedi.
HOUSTON, 4 novembre 2020 /PRNewswire/ -- Ascend Performance Materials ha annunciato oggi un aumento dei prezzi dei materiali intermedi.
LONDON, Nov. 4, 2020 /PRNewswire/ -- Burning Issues: The Global State of Tobacco Harm Reduction (GSTHR) 2020 published by UK public health agency Knowledge Action Change (KAC) demonstrates an urgent need to scale up tobacco harm reduction, which enables smokers to switch to safer nicotine products, eliminating the smoke that causes death and disease.
- Entering phase 2 clinical trial in the United States based on trial results in South Korea, India, and Australia
SUZHOU, China, Oct. 29, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today a licensing agreement with LegoChem Biosciences, Inc. ("LCB", KOSDAQ:141080), for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC").
- Influenza A (IVA) animal model confirmed 75% clinical symptom improvement compared to the control group
SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- On October 28, 2020, Yuyu Pharm (CEO Robert Wonsang Yu, KRX 000220) initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company's compliance system. During the introduction ceremony of ISO 37001 held at Yuyu Pharma's Seoul Office, CEO Robert Wonsang Yu kicked off the anti-bribery management system project and appointed Simon Kim, Director of Yuyu's Compliance Department, as the head of this project.
- The Fund continues the proven "Project Focused Company" investment strategy for early-stage drug development candidates
SUZHOU, China, Oct. 26, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced today an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that will allow these drugs to be competitively positioned in global markets against established treatments for the target indications.
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Resea...
World authorities from academia and industry discuss new technologies in a series of free webinars
PRAGUE, Oct. 19, 2020 /PRNewswire/ -- Zentiva reinforces its presence in Greece by signing a partnership with the company Lavipharm for representation, promotion, and distribution of its pharmaceutical products in Greece. With an established presence in Europe, Zentiva continues to strengthen its capabilities and service offering for people, by partnering with Lavipharm.
MECHELEN, Belgium and PARIS, Oct. 15, 2020 /PRNewswire/ -- Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086.
Trinseo announces mass balance certification for three material families
NYON, Switzerland, Oct. 11, 2020 /PRNewswire/ -- MedAlliance has announced enrolment of the first two patients in the PRISTINE registry with SELUTION SLR™ 018 DEB for the treatment of patients with Below The Knee disease (Chronic Limb Threatening Ischemia). This is the first DEB accepted by the FDA for its "Breakthrough Program". SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).
PRAGUE, Oct. 12, 2020 /PRNewswire/ -- The B2B Zent2U platform, powered by Zentiva, attends the online CPhI Festival of Pharma. The team will showcase its R&D pipeline assets for strategic partnerships through Zent2u. During this virtual congress, Zent2U representatives will meet with strategic stakeholders to discuss future collaboration leading to partnerships for success.
- Share sale brings into effect strategic collaboration agreement
- Merck out-licenses promising clinical-stage program to Novartis
59% of pet owners surveyed are unaware of the impact of seasonal change on their dogs and cats
- LyondellBasell to acquire 50 percent of certain Sasol assets in Louisiana
- Daewoong announced Enavogliflozin's result of phase 2 clinical trial in Korean type-2 diabetic patients at 2020 ICDM
